Navigation Links
Ariosa Diagnostics Welcomes New Board Member Michael A. Aicher
Date:2/25/2013

SAN JOSE, Calif., Feb. 25, 2013 /PRNewswire/ -- Ariosa Diagnostics, maker of the non-invasive Harmony™ Prenatal Test for detection of common genetic conditions, has announced the election of Michael A. Aicher to its Board of Directors.

(Logo: http://photos.prnewswire.com/prnh/20130225/SF62999LOGO)

Mr. Aicher has had a very successful career in the molecular diagnostics industry having spent the last 20 years in leadership positions at National Genetics Institute (NGI), a wholly-owned subsidiary of Laboratory Corporation of America® Holdings (LabCorp®), and LabCorp.

As the co-founder and CEO of NGI, Mr. Aicher steered the implementation of an initial treatment model for HCV and secured the first FDA-approved HIV/HCV PCR tests for plasma donor screening, with 15 million donations per year tested. Under various leadership positions at LabCorp, he helped drive revenue and margins within the esoteric testing business. Recognition for Mr. Aicher includes distinction as an Ernst & Young "Entrepreneur of the Year" for Emerging Technologies. Mr. Aicher recently took on the CEO position at Omicia, a DNA sequencing informatics company.

"Ariosa Diagnostics is honored to welcome Michael Aicher to the board. His multiple fields of expertise in strategy and operations within molecular testing will greatly complement the existing board. We are pleased that he will share his leadership and guidance with the team at Ariosa," said Ken Song , MD, CEO of Ariosa.

About Ariosa Diagnostics

Ariosa Diagnostics, Inc. is a molecular diagnostics company committed to innovating together to improve patient care. The flagship product, the Harmony Prenatal Test, is a safe, highly accurate and affordable prenatal test for maternal and fetal health. Led by an experienced team, Ariosa is using its proprietary technology to perform a directed analysis of cell-free DNA in blood. The Harmony Prenatal Test equips pregnant women and their healthcare providers with reliable information to make decisions regarding their health, without creating unnecessary stress or anxiety.

The company began operations in 2010 and is headquartered in San Jose, Calif. For more information, visit www.ariosadx.com. Follow us on Twitter @HarmonyPrenatal and on Facebook at Harmony Prenatal for Healthy Pregnancy.

CONTACT:
Jen Bruursema
Ariosa Diagnostics
408-229-7539
jbruursema@ariosadx.com


'/>"/>
SOURCE Ariosa Diagnostics
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Ariosa Diagnostics Announces Nationwide Launch of the Harmony™ Prenatal Test Through LabCorp
2. Ariosa Diagnostics Announces Publication of Study on Influential Factors Affecting Fetal DNA Concentration in Blood of Pregnant Women
3. Quest Diagnostics CE Marks Simplexa™ Test for Cytomegalovirus for Sale in Europe
4. SuperNova Diagnostics® to Present at the 23rd Annual Piper Jaffray Healthcare Conference in New York City
5. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
6. S.E.D. Labs to be Acquired by Quest Diagnostics
7. SuperNova Diagnostics® to Present at Biotech Showcase™ 2012 During JP Morgan Healthcare Conference January 9 - 12
8. Exagen Diagnostics Launches Cutting-Edge Lupus Diagnostic
9. QIAGEN Gains Rights to Genomic Biomarkers for Lung, Brain and Other Cancers to Expand its Pipeline of Companion Diagnostics
10. India In Vitro Diagnostics Market Outlook to 2017- Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture
11. Boulder Diagnostics Licenses Novel Rapid Detection Technology for Homocysteine and Related Compounds from Portland State University
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... Parallel ... clinical trials, announced today the Clinical Reach Virtual Patient Encounter CONSULT module ... circle with the physician and clinical trial team. , Using the CONSULT module, patients ...
(Date:6/27/2016)... June 27, 2016  Liquid Biotech ... funding of a Sponsored Research Agreement with The ... cells (CTCs) from cancer patients.  The funding will ... levels correlate with clinical outcomes in cancer patients ... will then be employed to support the design ...
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, ... second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical ... eBook by providing practical tips, tools, and strategies for clinical researchers. , “The ...
Breaking Biology Technology:
(Date:5/16/2016)... 2016   EyeLock LLC , a market leader ... of an IoT Center of Excellence in ... development of embedded iris biometric applications. EyeLock,s ... and security with unmatched biometric accuracy, making it the ... DNA. EyeLock,s platform uses video technology to deliver a ...
(Date:5/9/2016)... 9, 2016 Elevay is currently ... expanding freedom for high net worth professionals seeking travel ... globally connected world, there is still no substitute for ... duplicate sealing your deal with a firm handshake. This ... taking advantage of citizenship via investment programs like those ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... of Infosys (NYSE: INFY ), and Samsung SDS, ... partnership that will provide end customers with a more ... payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) ... financial services, but it also plays a fundamental part in ...
Breaking Biology News(10 mins):